ONE-YEAR CARDIOVASCULAR OUTCOME IN PATIENTS ON CLOPIDOGREL ANTI-PLATELET THERAPY AFTER ACUTE MYOCARDIAL INFARCTION

Dragana Stokanovic, Valentina N. Nikolic, Jelena Lilic, Svetlana R. Apostolovic, Milan Pavlovic, Vladimir S. Zivkovic, Dusan Milenkovic, Dane Krtinic, Gorana Nedin-Rankovic, Tatjana Jevtovic-Stoimenov

DOI Number
10.22190/FUMB170827012S
First page
55
Last page
60

Abstract


The aim of this study was to determine the risk factors in patients on clopidogrel anti-platelet therapy after acute myocardial infarction, for cardiovascular mortality, re-hospitalization and admission to emergency care unit. We followed 175 patients on dual antiplatelet therapy, with clopidogrel and acetylsalicylic acid, for 1 year after acute myocardial infarction, both STEMI and NSTEMI. Beside demographic and clinical characteristics, genetic ABCB1, CYP2C19 and CYP2C9 profile was analyzed using Cox-regression analysis. End-points used were: mortality, re-hospitalization and emergency care visits, all related to cardiovascular system. During the accrual and follow-up period, 8 patients (4.6%) died, mostly as a direct consequence of an acute myocardial infarction. Re-hospitalization was needed in 27 patients (15.4%), in nine patients (33.3%) with the diagnosis of re-infarction. Thirty-two patients (18.3%) were admitted to emergency care unit due to cardiovascular causes, up to 15 times during the follow-up. NSTEMI was an independent predictor of all three events registered (mortality OR=7.4, p<0.05; re-hospitalization OR=2.8, p<0.05); emergency care visit OR=2.4, p<0.05). Other significant predictors were related to kidney function (urea and creatinine level, creatinine clearance), co-morbidities such as arterial hypertension and decreased left ventricular ejection fraction, as well as clopidogrel dosing regimen. As a conclusion, it may be suggested that one of the most significant predictors of cardiovascular events (mortality, re-hospitalization and emergency care visits) is NSTEMI. Besides, clopidogrel administration according to up-to-date guidelines, with high loading doses and initial doubled maintenance doses, improves 1-year prognosis in patients with AMI.


Keywords

clopidogrel, acute myocardial infarction, cardiovascular outcome

Full Text:

PDF

References


Ilic D, Miljus D, Mickovski Katalina N, Plavsic S, Bozic Z. Incidence and mortality of acute coronary syndromes in Serbia. Serbian Acute Coronary Syndrome Registry Report No. 9. Miljus D, Mickovski Katalina N, Plavsic S, Bozic Z, editors. Beograd: Institute of Public Health of Serbia “Dr Milan Jovanovic Batut”; 2015.

Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J 2015; 36(19):1163–1170.

Krumholz HM, Lin Z, Drye EE, et al. An Administrative Claims Measure Suitable for Profiling Hospital Performance Based on 30-Day All-Cause Readmission Rates Among Patients With Acute Myocardial Infarction. Circ Cardiovasc Qual Outcomes 2011; 4:243–252.

Brown JR, Chang C-H, Zhou W, MacKenzie TA, Malenka DJ, Goodman DC. Health System Characteristics and Rates of Readmission After Acute Myocardial Infarction in the United States. J Am Heart Assoc 2014; 3:e000714.

Arnold S V., Smolderen KG, Kennedy KF, et al. Risk Factors for Rehospitalization for Acute Coronary Syndromes and Unplanned Revascularization Following Acute Myocardial Infarction. J Am Heart Assoc 2015; 4:e001352.

Rodriguez-Padial L, Elola FJ, Fernández-Pérez C, et al. Patterns of inpatient care for acute myocardial infarction and 30-day, 3-month and 1-year cardiac diseases readmission rates in Spain. Int J Cardiol 2017; 230:14–20.

Rana S, Tran T, Luo W, Phung D, Kennedy RL, Venkatesh S. Predicting unplanned readmission after myocardial infarction from routinely collected administrative hospital data. Aust Heal Rev 2014; 38(4):377.

Stokanovic D, Nikolic VN, Konstantinovic SS, et al. P-Glycoprotein Polymorphism C3435T Is Associated with Dose-Adjusted Clopidogrel and 2-Oxo-Clopidogrel Concentration. Pharmacology 2016; 97(3–4):101–106.

Wessler JD, Grip LT, Mendell J, Giugliano RP. The P-glycoprotein transport system and cardiovascular drugs. J Am Coll Cardiol 2013; 61(25):2495–2502.

Wang L, McLeod HL, Weinshilboum RM. Genomics and drug response. N Engl J Med 2011 Mar 24;364(12):1144–1153.

Montalescot G, Dallongeville J, Van Belle E, et al. STEMI and NSTEMI: are they so different? 1 year outcomes in acute myocardial infarction as defined by the ESC/ACC definition (the OPERA registry). Eur Heart J 2006; 28(12):1409–1417.

Fox CS, Muntner P, Chen AY, et al. Use of Evidence-Based Therapies in Short-Term Outcomes of ST-Segment Elevation Myocardial Infarction and Non–ST-Segment Elevation Myocardial Infarction in Patients With Chronic Kidney Disease. Circulation 2010; 121(3):357-365.

Jiang X-L, Samant S, Lewis JP, et al. Development of a physiology-directed population pharmacokinetic and pharmacodynamic model for characterizing the impact of genetic and demographic factors on clopidogrel response in healthy adults. Eur J Pharm Sci 2016;82:64–78.

Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33(20):2569–2619.

Ma W, Liang Y, Zhu J, Wang Y, Wang X. Meta-Analysis Appraising High Maintenance Dose Clopidogrel in Patients Who Underwent Percutaneous Coronary Intervention With and Without High On-Clopidogrel Platelet Reactivity. Am J Cardiol 2015; 115(5):592–601.

Karjalainen PP, Nammas W, Ylitalo A, et al. Long-term clinical outcome of titanium-nitride-oxide-coated stents versus everolimus-eluting stents in acute coronary syndrome: Final report of the BASE ACS trial. Int J Cardiol 2016; 222:275–280.

Sigurjonsdottir R, Barywani S, Albertsson P, Fu M. Long-term major adverse cardiovascular events and quality of life after coronary angiography in elderly patients with acute coronary syndrome. Int J Cardiol 2016; 222:481–485.

Phillip Owens A, Mackman N. The Antithrombotic Effects of Statins. Annu Rev Med 2014; 65(1):433–445.

Pundziute G, Schuijf JD, Jukema JW, Decramer I, Sarno G, Vanhoenacker PK, et al. Evaluation of plaque characteristics in acute coronary syndromes: non-invasive assessment with multi-slice computed tomography and invasive evaluation with intravascular ultrasound radiofrequency data analysis. Eur Heart J 2008; 29(19):2373–2381.

Yuan M-J, Pan Y-S, Hu W-G, et al. A pilot study of prognostic value of non-invasive cardiac parameters for major adverse cardiac events in patients with acute coronary syndrome treated with percutaneous coronary intervention. Int J Clin Exp Med 2015; 8(12):22440–22449.

Perelshtein Brezinov O, Klempfner R, Zekry S Ben, Goldenberg I, Kuperstein R. Prognostic value of ejection fraction in patients admitted with acute coronary syndrome: A real world study. Medicine 2017; 96(9):e6226.

Zhou D, Wan Z, Fan Y, Zhou J, Yuan Z. A combination of the neutrophil-to-lymphocyte ratio and the GRACE risk score better predicts PCI outcomes in Chinese Han patients with acute coronary syndrome. Anatol J Cardiol 2015; 15(12):995–1001.

Hyun DY, Jeong MH, Sim DS, Jeong YA, Cho KH, Kim MC, et al. Two-year clinical outcomes in stable angina and acute coronary syndrome after percutaneous coronary intervention of left main coronary artery disease. Korean J Intern Med 2016; 31(6):1084–1092.

Omstedt Å, Höijer J, Djärv T, Svensson P. Hypertension predicts major adverse cardiac events after discharge from the emergency department with unspecified chest pain. Eur Hear J Acute Cardiovasc Care 2016; 5(5):441–448.

Su J, Xu J, Li X, et al. ABCB1 C3435T polymorphism and response to clopidogrel treatment in coronary artery disease (CAD) patients: a meta-analysis. PLoS One 2012; 7(10):e46366.

Simon T, Verstuyft C, Mary-Krause M, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360(4):363–375.

Wallentin L, James S, Storey RF, et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 2010; 376(9749):1320–1328.




DOI: https://doi.org/10.22190/FUMB170827012S

Refbacks

  • There are currently no refbacks.


© University of Niš, Serbia
Creative Commons licence CC BY-NC-ND
ISSN 0354-4699 (Print)
ISSN 2406-050X (Online)